Early observations and pilot data that first suggested a new direction
Malignant middle cerebral artery (MCA) infarction carries a mortality rate exceeding 80% with conservative management alone. Early observational studies and case series from the 1990s suggested that decompressive hemicraniectomy could dramatically reduce mortality by alleviating rising intracranial pressure. These non-randomized reports showed survival benefits but raised questions about functional outcomes and quality of life among survivors. The surgical neurosurgery community recognized the need for rigorous randomized evidence to determine whether survival gains translated into acceptable functional recovery.
Landmark RCTs and pivotal trials that established the evidence base
Three European RCTs — DECIMAL (France), DESTINY (Germany), and HAMLET (Netherlands) — were conducted simultaneously to evaluate decompressive craniectomy in patients under 60 years with malignant MCA infarction. All three trials were stopped early due to clear mortality benefit, and a pre-planned pooled analysis of 93 patients published in Lancet Neurology (2007) demonstrated a striking reduction in mortality from 71% to 22% at 12 months. The pooled analysis also showed that more survivors in the surgery group achieved a modified Rankin Scale score of 0-3 (favorable outcome), though a significant proportion survived with moderate-to-severe disability (mRS 4). This evidence fundamentally shifted the treatment paradigm for younger patients with massive hemispheric stroke.
Follow-up studies, subgroup analyses, and real-world validation
The DESTINY-II trial (2014) extended the evidence to patients aged 61 and older, a population excluded from the original trials. This landmark RCT of 112 patients demonstrated that decompressive surgery reduced mortality from 76% to 43% in the elderly, but the majority of survivors had severe disability (mRS 4-5), with none achieving mRS ≤2. The trial highlighted a critical ethical dilemma: surgery saves lives but often results in outcomes many patients and families consider unacceptable. Long-term follow-up studies of the original pooled cohort confirmed sustained survival benefits at 3 years but also revealed persistent significant disability and reduced quality of life in many survivors.
Integration into clinical practice guidelines and recommendations
The AHA/ASA 2019 guidelines for the management of acute ischemic stroke gave a Class I recommendation for decompressive craniectomy in patients ≤60 years who deteriorate neurologically from malignant cerebral edema despite medical therapy, recommending surgery within 48 hours of symptom onset. For patients over 60, the guidelines note the uncertain benefit-to-harm ratio and recommend shared decision-making. The European Stroke Organisation similarly endorsed early decompressive surgery in younger patients while emphasizing the importance of discussing likely functional outcomes with families before proceeding.
AHA/ASA
Decompressive craniectomy with dural expansion is recommended for patients ≤60 years with malignant MCA infarction who deteriorate despite medical therapy (Class I, Level A)
European Stroke Organisation
Decompressive surgery should be considered within 48 hours of symptom onset in patients aged 18-60 with malignant MCA infarction
Now
Current standard of care and ongoing research directions
Current practice strongly favors decompressive craniectomy for patients under 60 with malignant MCA infarction, ideally performed within 48 hours. For elderly patients, the decision remains highly individualized and depends on pre-morbid functional status, patient/family values, and willingness to accept potential severe disability. Ongoing research focuses on better prognostic tools to identify which patients will achieve acceptable outcomes, optimal timing of surgery, and the role of hypothermia as an adjunctive therapy. The concept of patient-centered outcome assessment has become central to this field, with increasing recognition that survival alone is an insufficient metric for surgical success.
What is the optimal timing for decompressive craniectomy in malignant MCA infarction?+
Evidence from the pooled analysis of DECIMAL, DESTINY, and HAMLET supports surgery within 48 hours of symptom onset. Earlier surgery (before clinical herniation) appears to produce better outcomes, though the exact optimal window remains debated. Most guidelines recommend not delaying beyond 48 hours once malignant edema is identified.
Should decompressive craniectomy be offered to patients over 60?+
DESTINY-II showed that surgery reduces mortality in patients over 60, but nearly all survivors have severe disability (mRS 4-5). Guidelines recommend shared decision-making with families, emphasizing realistic functional outcome expectations. Pre-morbid function and patient values should guide the decision.
What functional outcomes can be expected after decompressive craniectomy?+
In patients under 60, the pooled analysis showed approximately 43% achieve mRS 0-3 (independent or requiring some help) at 12 months, compared to 21% with conservative management. However, a significant proportion survive with moderate-to-severe disability. Quality of life studies show many survivors report acceptable quality of life despite significant disability.
